Compare · BLFS vs TMDX
BLFS vs TMDX
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.41B, about 1.8x BLFS ($1.33B).
- Over the past year, BLFS is up 25.5% and TMDX is down 43.2% - BLFS leads by 68.7 points.
- TMDX has been more active in the news (12 items in the past 4 weeks vs 2 for BLFS).
- TMDX has more recent analyst coverage (18 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- TransMedics Group Inc.
- Price
- $27.62+1.54%
- $73.75+5.77%
- Market cap
- $1.33B
- $2.41B
- 1M return
- +28.11%
- -22.32%
- 1Y return
- +25.49%
- -43.19%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 2
- 12
- Recent ratings
- 8
- 18
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest BLFS
- BioLife Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Large owner Casdin Partners Master Fund, L.P. sold $28,125,000 worth of shares (1,200,000 units at $23.44) (SEC Form 4)
- SEC Form 10-Q filed by BioLife Solutions Inc.
- BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BioLife Solutions Reports First Quarter 2026 Financial Results
- Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.
- BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
- SEC Form 4 filed by Mathew Aby J.
- SEC Form 4 filed by Berard Todd
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.